CD274 and neoplasm: Given the tremendous impact that immune checkpoint inhibitors targeting T cells have had on cancer treatment and the recent approval of these drugs for PD-L1 positive CC [20], we undertook a detailed T-cell-centric analysis of the tumor immune landscape differences between HPV-positive and HPV-negative CC.